Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anaprazole in Bismuth Quadruple Therapy for Helicobacter Pylori Eradication
NCT07606833Phase 3Not yet recruiting
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jun 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Anaprazole in Helicobacter pylori infection, sponsored by Xuanzhu Biopharmaceutical. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Anaprazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07606833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606833.